Ascend Laboratories, LLC recalls
Ascend Laboratories, LLC is named on 16 recalls in Recall Relay's records since November 2023, from FDA (25 recalled products: FDA lists each product as its own recall); the most recent was October 6, 2026.
All 25 recalled products, newest first.
-
Class IIofficial
Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsOut of specification due to dissolution.
-
Class IIIofficial
Ascend Laboratories, LLC recalls Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
-
Class IIIofficial
Ascend Laboratories, LLC recalls Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
-
Class IIIofficial
Ascend Laboratories, LLC recalls Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
-
Class IIofficial
Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications; Olmesartan Medoxomil content below specifications
-
Class IIIofficial
Ascend Laboratories, LLC recalls Dabigatran etexilate CapsulesFailed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
-
Class IIIofficial
Ascend Laboratories, LLC recalls Dabigatran etexilate CapsulesFailed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
-
Class IIofficial
Ascend Laboratories, LLC recalls Minocycline Hydrochloride Extended-Release TabletsFailed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis
-
Class IIofficial
Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications: Olmesartan Medoxomil content below specifications
-
Class IIofficial
Ascend Laboratories, LLC recalls Ascend LaboratoriesFailed Dissolution Specifications
-
Class IIofficial
Ascend Laboratories, LLC recalls Atorvastatin Calcium Tablets USPFailed Dissolution Specifications
-
Class IIofficial
Ascend Laboratories, LLC recalls Atorvastatin Calcium Tablets USPFailed Dissolution Specifications
-
Class IIofficial
Ascend Laboratories, LLC recalls Atorvastatin Calcium Tablets USPFailed Dissolution Specifications
-
Class IIofficial
Ascend Laboratories, LLC recalls Atorvastatin Calcium Tablets USPFailed Dissolution Specifications
-
Class IIofficial
Ascend Laboratories, LLC recalls Aripiprazole TabletsSuperpotent drug
-
Class IIofficial
Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications: low dissolution results
-
Class IIofficial
Ascend Laboratories, LLC recalls Rizatriptan Benzoate TabletsCGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
-
Class IIofficial
Ascend Laboratories, LLC recalls Rizatriptan Benzoate TabletsCGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
-
Class IIofficial
Ascend Laboratories, LLC recalls Cephalexin for Oral SuspensionFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.
-
Class IIofficial
Ascend Laboratories, LLC recalls Cephalexin for Oral SuspensionFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.
-
Class IIofficial
Ascend Laboratories, LLC recalls Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
-
Class IIofficial
Ascend Laboratories, LLC recalls Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
-
Class IIofficial
Ascend Laboratories, LLC recalls Mycophenolic Acid Delayed-Release Tablets USPFailed Dissolution Specifications
-
Class IIofficial
Ascend Laboratories, LLC recalls Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation Specification: Out of specification for organic impurities
-
Class IIofficial
Ascend Laboratories, LLC recalls Ibuprofen and Famotidine Tablets 800mg/26.6mgPresence of Foreign Tablet/Capsule: A stray Rasagiline Mesylate 1 mg tablet was discovered in an unopened bottle of Ibuprofen and Famotidine.
This page groups recalls by the company name the agency printed, so it can include different companies with similar names, and a recall may name a store or distributor rather than the maker. It counts the recalls in Recall Relay's records, not a company's whole history; an FDA recall that lists several products counts once. Open a recall to see its details and the agency's official notice, which is always the final word. Recall Relay isn't affiliated with any agency or with the companies named here.
Severity labels say where they come from: “official” is the agency's own class, “advisory” is based on the agency's safety warning, and “est. risk” is Recall Relay's estimate from the hazard description, not an agency classification.
Hear about the next one
Recall Relay can email you when a new recall mentions Ascend Laboratories, LLC or any words you choose. Start with a free key (no card needed), then set up alerts on your account page.
Get recall alerts